FDA Provides Akebia Therapeutics a Path Forward for Vadadustat

FDA denies formal dispute resolution, but outlines path to resubmit NDA for dialysis-dependent patients without new clinical studies Akebia plans to request Type A meeting and then resubmit NDA CAMBRIDGE, Mass., May 30, 2023 /PRNewswire/ --...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news